Cultivated Fish, Shrimp & the End of Aquaculture Suffering
Wild-caught and farmed seafood represents one of the largest sources of animal suffering on Earth. By weight, more fish are killed for food each year than all other farmed animals combined — with estimates ranging from 0.8 to 2.3 trillion wild fish killed annually, plus hundreds of billions more in aquaculture.
Cultivated (cell-based) seafood uses the same fundamental technology as cultivated meat:
Pioneering cultivated shrimp; shrimp cells are particularly well-suited to cultivation due to their biology. First cultivated shrimp tasting in 2019; working toward commercial scale.
Focused on whole-muscle fish products; demonstrated yellowtail, mahi-mahi, and bluefin tuna prototypes. Partnership with major Japanese seafood distributor Mitsubishi.
Cultivated salmon; raised $100M+ in funding; focus on sushi-grade salmon with authentic texture. One of the most advanced US companies in regulatory pathway.
Cultivated fish maw (swim bladder) and grouper; targeting Asian premium seafood markets where wild-caught prices are extremely high.
Bluefin tuna cultivation; one of the highest-value and most welfare-concerning wild fisheries — a critical target for cultivated seafood.
Cultivated lobster and crab; targeting the premium crustacean market where welfare concerns (boiling alive) are significant.
The FDA and USDA share regulatory oversight of cultivated meat and seafood. Upside Foods and Good Meat received FDA clearance for cultivated chicken in 2023 — establishing the regulatory pathway. Cultivated seafood companies are advancing through FDA consultation processes; first approvals expected 2025–2027.
Singapore was the first country to approve cultivated meat for sale (Good Meat chicken, 2020) and has positioned itself as a global hub for alternative protein regulation. Several cultivated seafood companies are using Singapore as their regulatory launch market.
Novel Food Regulation applies to cultivated seafood; the process is more complex than in the US or Singapore, with timelines potentially extending to 2027–2028 for first approvals.
Cell-based seafood represents one of the most promising long-term pathways to dramatically reducing aquatic animal suffering. Given the enormous scale of fish and crustacean suffering in both wild capture and aquaculture, even partial market penetration by cultivated seafood could have welfare impacts exceeding most other interventions combined. Supporting this technology — through consumer interest, investment advocacy, and policy support — is one of the highest-leverage actions available to animal welfare advocates.